WO2008152423A3 - Treatment of inflammation or autoimmune diseases with sulphated compounds - Google Patents
Treatment of inflammation or autoimmune diseases with sulphated compounds Download PDFInfo
- Publication number
- WO2008152423A3 WO2008152423A3 PCT/GB2008/050437 GB2008050437W WO2008152423A3 WO 2008152423 A3 WO2008152423 A3 WO 2008152423A3 GB 2008050437 W GB2008050437 W GB 2008050437W WO 2008152423 A3 WO2008152423 A3 WO 2008152423A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- present
- relates
- dosage forms
- unit dosage
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 8
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 206010061218 Inflammation Diseases 0.000 title 1
- 230000004054 inflammatory process Effects 0.000 title 1
- 239000002552 dosage form Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 150000002772 monosaccharides Chemical class 0.000 abstract 3
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 2
- 208000010643 digestive system disease Diseases 0.000 abstract 2
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 2
- 125000003132 pyranosyl group Chemical group 0.000 abstract 2
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 abstract 2
- 229960004291 sucralfate Drugs 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- 229930006000 Sucrose Natural products 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000012986 modification Methods 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 239000005720 sucrose Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to sulphated compounds containing one to twelve monosaccharide subunits, for the treatment or prevention of anon-gastrointestinal disease or conditionby gastrointestinal absorption, wherein none of the monosaccharide subunits is pyranosyl with N-substitution at the 2-position relative to the anomeric carbon of the pyranosyl subunit. The present invention also relates to corresponding methods of treating or preventing anon-gastrointestinal disease or condition. Additionally, the present invention relates to a method of modifying, or testing for a modification in,the level of a cytokine in vivo, ex vivoor in vitro, said method comprising contacting a sulphated compound with a cell, wherein the compound comprises at least one monosaccharide subunit. The present invention also relates to unit dosage forms comprising at least 2.5g of any of the above compounds, to unit dosage forms comprising the molar equivalent of at least 1 g of any of the above compounds in theirfree acid and/or base form, and to unit dosage forms comprising any of the above compounds other than sucralfate.Preferred compounds of the present invention are sucrose octasulphate and sucralfate.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0711139.6 | 2007-06-11 | ||
| GB0711139A GB2450087A (en) | 2007-06-11 | 2007-06-11 | Use of sulphated saccharides in the treatment of inflammatory and/or auto-immune diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008152423A2 WO2008152423A2 (en) | 2008-12-18 |
| WO2008152423A3 true WO2008152423A3 (en) | 2009-02-19 |
Family
ID=38319060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/GB2008/050437 WO2008152423A2 (en) | 2007-06-11 | 2008-06-11 | Treatment of inflammation or autoimmune diseases with sulphated compounds |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB2450087A (en) |
| WO (1) | WO2008152423A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201000196D0 (en) | 2010-01-07 | 2010-02-24 | Galvez Julian M | Novel combination |
| DK2646037T3 (en) * | 2010-12-01 | 2019-03-04 | Univ Australian National | use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994028020A1 (en) * | 1993-05-18 | 1994-12-08 | Bukh Meditec A/S | A method for the preparation of interferons |
| WO1996035700A1 (en) * | 1995-05-10 | 1996-11-14 | Glycomed Incorporated | Saccharopeptides and derivatives thereof |
| US5908836A (en) * | 1987-12-21 | 1999-06-01 | Bar-Shalom; Daniel | Protecting skin from radiation damage using sulphated sugars |
| WO2006017752A2 (en) * | 2004-08-05 | 2006-02-16 | Ivax Corporation | Sulfated oligosaccharides |
| WO2008059003A1 (en) * | 2006-11-14 | 2008-05-22 | Diosamine Development Corporation | Novel compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK505488D0 (en) * | 1987-12-21 | 1988-09-09 | Bar Shalom Daniel | MEDIUM AND USE OF SAME |
| IT1226549B (en) * | 1988-07-12 | 1991-01-24 | Resa Farma | PHARMACEUTICAL COMPOSITIONS WITH ANALGESIC AND ANTI-INFLAMMATORY ACTIVITY FOR ORAL USE, EQUIPPED WITH EXCELLENT PALATABILITY AND FREE FROM IRRITATING EFFECTS ON MUCOSES. |
| JP3163358B2 (en) * | 1997-02-28 | 2001-05-08 | 経済産業省産業技術総合研究所長 | Sulfated oligosaccharide compounds |
| JP2000143686A (en) * | 1997-02-28 | 2000-05-26 | Agency Of Ind Science & Technol | Sulfated oligosaccharide compound |
| US20040039042A1 (en) * | 2002-08-23 | 2004-02-26 | Fleming Thomas E. | Method of transdermal drug delivery |
| JP4850402B2 (en) * | 2004-10-07 | 2012-01-11 | ロート製薬株式会社 | Oral preparation |
-
2007
- 2007-06-11 GB GB0711139A patent/GB2450087A/en not_active Withdrawn
-
2008
- 2008-06-11 WO PCT/GB2008/050437 patent/WO2008152423A2/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5908836A (en) * | 1987-12-21 | 1999-06-01 | Bar-Shalom; Daniel | Protecting skin from radiation damage using sulphated sugars |
| WO1994028020A1 (en) * | 1993-05-18 | 1994-12-08 | Bukh Meditec A/S | A method for the preparation of interferons |
| WO1996035700A1 (en) * | 1995-05-10 | 1996-11-14 | Glycomed Incorporated | Saccharopeptides and derivatives thereof |
| WO2006017752A2 (en) * | 2004-08-05 | 2006-02-16 | Ivax Corporation | Sulfated oligosaccharides |
| WO2008059003A1 (en) * | 2006-11-14 | 2008-05-22 | Diosamine Development Corporation | Novel compounds |
Non-Patent Citations (5)
| Title |
|---|
| BURCH R M ET AL: "Sucralfate induces prolifetion of dermal fibroblasts and keratinocytes in culture and granulation tissue formation in full-thickness skin wounds", AGENTS AND ACTIONS, BIRKHAEUSER VERLAG, BASEL, CH, vol. 34, no. 1-2, 1 January 1991 (1991-01-01), pages 229 - 231, XP002962047, ISSN: 0065-4299 * |
| CAHALON LIORA ET AL: "Heparin disaccharides inhibit tumor necrosis factor-alpha production by macrophages and arrest immune inflammation in rodents", INTERNATIONAL IMMUNOLOGY, vol. 9, no. 10, 1997, pages 1517 - 1522, XP002504319, ISSN: 0953-8178 * |
| EAMLAMNAM K ET AL: "Effects of Aloe vera and sucralfate on gastric microcirculatory changes, cytokine levels and gastric ulcer healing in rats", WORLD JOURNAL OF GASTROENTEROLOGY, WJG PRESS, CN, vol. 12, no. 13, 7 April 2006 (2006-04-07), pages 2034 - 2039, XP008098731, ISSN: 1007-9327 * |
| SCHOELL ISABELLA ET AL: "Anti-ulcer treatment during pregnancy induces food allergy in mouse mothers and a Th2-bias in their offspring", FASEB JOURNAL, vol. 21, no. 4, April 2007 (2007-04-01), pages 1264 - 1270, XP002504320, ISSN: 0892-6638 * |
| SLOMIANY B L ET AL: "Effect of sucralfate on gastric mucosal inflammatory responses induced by Helicobacter pylori lipopolysaccharide", SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, vol. 33, no. 9, September 1998 (1998-09-01), pages 916 - 922, XP008095949, ISSN: 0036-5521 * |
Also Published As
| Publication number | Publication date |
|---|---|
| GB0711139D0 (en) | 2007-07-18 |
| GB2450087A (en) | 2008-12-17 |
| WO2008152423A2 (en) | 2008-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2370478T3 (en) | ANTI-ADHESIVE CARBOHYDRATES. | |
| NO20084931L (en) | Pharmaceutical compositions | |
| WO2004041195A3 (en) | Pharmaceutical formulations targeting specific regions of the gastrointestinal tract | |
| MX2007012045A (en) | Methods, compositions, and formulations for preventing or reducing adverse effects in a patient. | |
| JP2004535430A5 (en) | ||
| WO2011035335A3 (en) | Stabilized liquid and lyophilized adamts13 formulations | |
| WO2008155900A1 (en) | Glp-1 peptide having sugar chain attached thereto | |
| WO2005092929A8 (en) | Hyaluronic acid butyric esters with a low degree of substitution, procedure for their preparation and use | |
| EP2478895A3 (en) | Compositions for treating esophageal disorders | |
| EP1561760A3 (en) | Low molecular weight heparin salt with thriethanolamine | |
| US11248063B2 (en) | Derivatives of N-desulfated glycosaminoglycans and use as drugs | |
| WO2008152423A3 (en) | Treatment of inflammation or autoimmune diseases with sulphated compounds | |
| WO1996001278A1 (en) | Process for producing desulfated polysaccharide, and desulfated heparin | |
| PL375693A1 (en) | Aldonic acid esters, methods for producing the same, and methods for producing pharmaceutical active ingredients coupled to polysaccharides or polysaccharide derivatives on free amino groups | |
| WO2008096547A1 (en) | Anti-tumor composition comprising tissue-accumulating chitosan gel | |
| JP2004536825A5 (en) | ||
| WO2007109731A3 (en) | Healing powder and method of use thereof | |
| HK1129071A1 (en) | Use of an indazolemethoxyalkanoic acid for reducing triglyceride, cholesterol and glucose levels | |
| US20220233578A1 (en) | Compositions and methods of using same for tissue regeneration | |
| PL376017A1 (en) | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells | |
| EP2515910B1 (en) | Use of polysaccharides in the treatment of stress and anxiety | |
| Heitlinger et al. | Transport of glucose polymer-derived glucose by rabbit jejunum | |
| EP1790351A8 (en) | Permucosal composition and method of improving permucosal absorption | |
| AP1820A (en) | Use of specific dose of fondaparinux sodium for the treatment of ACS. | |
| JP2005509007A5 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08762547 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 08762547 Country of ref document: EP Kind code of ref document: A2 |